PMID- 24325471
OWN - NLM
STAT- MEDLINE
DCOM- 20140404
LR  - 20221207
IS  - 1557-7430 (Electronic)
IS  - 1044-5498 (Linking)
VI  - 33
IP  - 2
DP  - 2014 Feb
TI  - Significance of MDM2-309 polymorphisms and induced corresponding plasma MDM2 
      levels in susceptibility to laryngeal squamous cell carcinoma.
PG  - 88-94
LID - 10.1089/dna.2013.2220 [doi]
AB  - The tumor suppressor p53 plays a crucial role in maintaining genomic stability 
      and tumor prevention. Murine double-minute 2 (MDM2) oncoprotein plays a pivotal 
      role in regulating p53, and the single-nucleotide polymorphism (SNP) 309T/G SNP 
      in the promoter region of Mdm2 has been shown to be associated with increased 
      risk of cancer. We investigated the association between Mdm2-309 promoter 
      polymorphism, plasma MDM2 levels, and risk of laryngeal squamous cell carcinoma 
      (LSCC). In this case-control study, 146 patients with LSCC, 61 patients with 
      vocal leukoplakia, and 212 healthy controls were genotyped for the Mdm2-309 T/G 
      gene using pyrosequencing. Plasma MDM2 levels were also analyzed by enzyme-linked 
      immunosorbent assay (ELISA). Patients with LSCC had a significantly lower 
      frequency of GT at Mdm2-309 (odds ratio [OR]=0.50, p=0.02) than controls. The 
      proportion of GT heterozygotes in advanced stage cases were less than that in the 
      initial stage patients (OR: 0.36 vs. 0.63; p=0.007 and 0.16). The same result was 
      found between cases with and without lymph node metastases (OR: 0.45 vs. 0.52; 
      p=0.075 and 0.04). Moreover, the plasma Mdm2 concentrations of LSCC patients 
      (343.36+/-14.8 pg/mL) were significantly higher than those in controls 
      (255.76+/-8.2 pg/mL; p<0.01) and vocal leukoplakia patients (301.42+/-8.6 pg/mL; 
      p<0.05). Patients in advanced stages and with lymph node metastasis had higher 
      plasma MDM2 levels, while the GT genotypes (308.06+/-18.9 pg/mL; p=0.037) had lower 
      MDM2 plasma levels than the TT genotypes (369.00+/-25.2 pg/mL). The Mdm2 SNP309 G 
      allele is implicated as an important LSCC and a vocal leukoplakia protective 
      factor in the Chinese Han Population, and the proportion of GT genotype was lower 
      in advanced LSCC patients and lymph node metastasis patients. Moreover, Mdm2-309 
      GT genotype patients had a lower plasma MDM2 level than the TT genotypes.
FAU - Zhou, Jian
AU  - Zhou J
AD  - 1 Department of Otolaryngology, Eye Ear Nose and Throat Hospital, Fudan 
      University , Shanghai, China .
FAU - Liu, Fei
AU  - Liu F
FAU - Zhang, Duo
AU  - Zhang D
FAU - Chen, Bin
AU  - Chen B
FAU - Li, Qing
AU  - Li Q
FAU - Zhou, Lin
AU  - Zhou L
FAU - Lu, Li-Ming
AU  - Lu LM
FAU - Tao, Lei
AU  - Tao L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131210
PL  - United States
TA  - DNA Cell Biol
JT  - DNA and cell biology
JID - 9004522
RN  - 0 (DNA Primers)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.3.2.27 (MDM2 protein, human)
RN  - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2)
SB  - IM
MH  - Animals
MH  - Asian People/*genetics
MH  - Base Sequence
MH  - Carcinoma, Squamous Cell/*genetics
MH  - Case-Control Studies
MH  - DNA Primers/genetics
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Genetic Predisposition to Disease/*genetics
MH  - Genotype
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics
MH  - Logistic Models
MH  - Mice
MH  - Molecular Sequence Data
MH  - Neoplasm Metastasis/genetics
MH  - Odds Ratio
MH  - Polymorphism, Single Nucleotide/*genetics
MH  - Proto-Oncogene Proteins c-mdm2/*blood/*genetics
MH  - Sequence Analysis, DNA
MH  - Tumor Suppressor Protein p53/metabolism
EDAT- 2013/12/12 06:00
MHDA- 2014/04/05 06:00
CRDT- 2013/12/12 06:00
PHST- 2013/12/12 06:00 [entrez]
PHST- 2013/12/12 06:00 [pubmed]
PHST- 2014/04/05 06:00 [medline]
AID - 10.1089/dna.2013.2220 [doi]
PST - ppublish
SO  - DNA Cell Biol. 2014 Feb;33(2):88-94. doi: 10.1089/dna.2013.2220. Epub 2013 Dec 
      10.